Pharsight

Namzaric patents expiration

NAMZARIC's oppositions filed in EPO
NAMZARIC Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338485 ALLERGAN Compositions for the treatment of CNS-related conditions
Nov, 2025

(1 year, 7 months from now)

US8173708 ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 7 months from now)

US8362085 ALLERGAN Method for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 7 months from now)

US8338486 ALLERGAN Methods for the treatment of CNS-related conditions
Nov, 2025

(1 year, 7 months from now)

US8283379 ALLERGAN Methods and compositions for the treatment of CNS-related conditions
Nov, 2025

(1 year, 7 months from now)

US8580858 ALLERGAN Compositions for the treatment of CNS-related conditions
Nov, 2025

(1 year, 7 months from now)

US8329752 ALLERGAN Composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 7 months from now)

US8598233 ALLERGAN Method for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 7 months from now)

US8168209 ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 7 months from now)

US8293794 ALLERGAN Methods and compositions for the treatment of CNS-related conditions
Nov, 2025

(1 year, 7 months from now)

US8329752

(Pediatric)

ALLERGAN Composition for administering an NMDA receptor antagonist to a subject
May, 2026

(2 years from now)

US8283379

(Pediatric)

ALLERGAN Methods and compositions for the treatment of CNS-related conditions
May, 2026

(2 years from now)

US8173708

(Pediatric)

ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject
May, 2026

(2 years from now)

US8362085

(Pediatric)

ALLERGAN Method for administering an NMDA receptor antagonist to a subject
May, 2026

(2 years from now)

US8598233

(Pediatric)

ALLERGAN Method for administering an NMDA receptor antagonist to a subject
May, 2026

(2 years from now)

US8168209

(Pediatric)

ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject
May, 2026

(2 years from now)

US8039009 ALLERGAN Modified release formulations of memantine oral dosage forms
Mar, 2029

(4 years from now)

US8039009

(Pediatric)

ALLERGAN Modified release formulations of memantine oral dosage forms
Sep, 2029

(5 years from now)

US8058291 ALLERGAN Methods and compositions for the treatment of CNS-related conditions
Dec, 2029

(5 years from now)

Namzaric is owned by Allergan.

Namzaric contains Donepezil Hydrochloride; Memantine Hydrochloride.

Namzaric has a total of 19 drug patents out of which 0 drug patents have expired.

Namzaric was authorised for market use on 23 December, 2014.

Namzaric is available in capsule, extended release;oral dosage forms.

Namzaric can be used as memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type.

The generics of Namzaric are possible to be released after 05 December, 2029.

Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 December, 2014

Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of NAMZARIC before it's drug patent expiration?
More Information on Dosage

NAMZARIC family patents

Family Patents